When was the last time you achieved the impossible? If that thought feels overwhelming, you might want to pause here, but if it sparks excitement…read on
In 2015, we pioneered a “moneyball for biotech” approach, pooling projects and promising early-stage research from academia together under one financial umbrella to reduce risk and unleash innovation. This model allows science and small teams of experts to lead the way. We build bridges to groundbreaking advancements in rare disease, and develop life-changing medicines for patients with unmet needs as fast as humanly possible.
Together we define white space, push boundaries and empower people to solve problems. If you're someone who defies convention, join us and work alongside some of the most respected minds in the industry. Together, we'll ask "why not?" and help reengineer the future of biopharma.
QED Therapeutics, an affiliate within BridgeBio Pharma, focuses on developing targeted treatments for FGFR-driven skeletal dysplasias, particularly Achondroplasia. Achondroplasia is the most common form of genetically-driven short stature, which causes potentially debilitating medical complications. With our experimental therapeutic candidate, infigratinib, we seek to provide an option to children living with Achondroplasia and their families.
We are seeking a Sr. Manager/Associate Director, Regulatory Program Management to support the Achondroplasia and related skeletal dysplasia regulatory team. This individual will partner closely with the Sr. Director, Program Management, SVP, Regulatory Affairs, and cross-functional team members to enable delivering on key regulatory and filing goals for the program. This position requires understanding of and experience in biotech/drug development, regulatory filings and project management for late-stage clinical programs. The ideal candidate will be developing leadership skills and will have exceptional attention to detail and organizational skills. The role requires someone who can organize projects effectively in a rapidly changing, fast-paced setting. We are looking for a self-starter that will help drive our achondroplasia program through to MAA and NDA filings and drive successful execution of our regulatory plans. Previous experience in a regulatory project management role within the pharmaceutical or biotech industry & experience with filings are a must.
QED Therapeutics, an affiliate of BridgeBio Pharma, focuses on developing targeted treatments for FGFR-driven skeletal dysplasias, particularly Achondroplasia. Achondroplasia is the most common form of genetically driven short stature, which causes potentially debilitating medical complications. With our experimental therapeutic candidate infigratinib, we seek to provide a treatment option to children living with Achondroplasia and their families.
This a U.S-based remote role that will require quarterly, or as needed visits to our San Francisco, CA or Palo Alto, CA offices for company events and critical business meetings.
We have high expectations for our team members. We make sure those working hard for patients are rewarded and cared for in return.
People are part of our growth and success story - from discovery to active drug trials and FDA pipelines, there are endless opportunities for skill development and internal mobility
At BridgeBio, we strive to provide a market-competitive total rewards package, including base pay, an annual performance bonus, company equity, and generous health benefits. Below is the anticipated salary range for candidates for this role who will work in California. The final salary offered to a successful candidate will depend on several factors that may include but are not limited to the type and length of experience within the job, type, and length of experience within the industry, educational background, location of residence and performance during the interview process. BridgeBio is a multi-state employer, and this salary range may not reflect positions based in other states.
$150,000 - $220,000 USD